340B Drug Pricing Program
The AHA and five other health care organizations today sent a letter to Health and Human Services Secretary Xavier Becerra urging him to stop the actions of six drug companies that are denying 340B discounts on prescription drugs sold to hospitals treating a large percentage of low-income and rural…
The leaders of six major organizations representing hospitals and pharmacists sent a letter to U.S. Health and Human Services (HHS) Secretary Xavier Becerra urging him to halt the actions of six drug companies that are denying 340B discounts on prescription drugs sold to hospitals treating a large…
The AHA and five other health care organizations sent the attached letter to HHS Secretary Becerra urging him to stop the actions of six drug companies that are denying 340B discounts on prescription drugs sold to hospitals treating a large percentage of low-income and rural Americans.
The AHA today urged the Department of Health and Human Services to ensure hospitals currently participating in the 340B Drug Pricing Program continue to have access to the program despite changes in their payer mix as a result of the COVID-19 public health emergency.
Motion and Memorandum in Support of Motion to Intervene NOVO NORDISK v Cochran (March 2, 2021)
AHA urges the Department of Health and Human Services (HHS) to ensure hospitals currently participating in the 340B Drug Pricing Program continue to have access to the program despite changes in their payer mix as a result of the COVID-19 public health emergency (PHE).
IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY
Government’s Opposition to Motion to Intervene - AstraZeneca v. Cochran (March 12, 2021)
AstraZeneca’s Opposition to Motion to Intervene (March 12, 2021) Insert